Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Hartmut Döhner, Courtney D. DiNardo, Frederick Appelbaum, Charles Craddock, Hervé Dombret, Benjamin L. Ebert, Pierre Fenaux, Lucy A. Godley, Robert P. Hasserjian, Richard A. Larson, Ross L. Levine, Yasushi Miyazaki, Dietger Niederwieser, Gert J. Ossenkoppele, Christoph Röllig, Jorge Sierra, Eytan M. Stein, Martin S. Tallman, Hwei‐Fang Tien, Jianxiang Wang, Agnieszka Wierzbowska, Andrew H. Wei, Bob Löwenberg
Abstract
ABSTRACT: The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
Topics & Concepts
MedicineIntensive care medicinePopulationRisk assessmentMEDLINEInternal medicineOncologyEnvironmental healthLawComputer scienceComputer securityPolitical scienceAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsAcute Lymphoblastic Leukemia research